Browse by author
Lookup NU author(s): Dr Paraq Singhal,
Professor Roy Taylor
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The effect of repaglinide and gliclazide on postmeal suppression of endogenous glucose production (EGP) has been studied using a variable-rate tracer methodology. Groups of age-, sex-, and weight-matched type 2 diabetic subjects randomized to gliclazide or repaglinide were studied after ingesting a standard mixed meat (550 kcal; 67% carbohydrate, 19% fat, 14% protein). Plasma glucose profiles were similar in each group and markedly different from that of a nondiabetic control group. Endogenous glucose production was similar basally (3.01 +/- 0.30 vs 3.06 +/- 0.19 mg/kg per minute, gliclazide and repaglinide, respectively). After glucose ingestion, EGP declined rapidly in both the groups until 30 minutes and the greatest suppression was reached earlier in the repaglinide group [0.88 mg/kg per minute at 120 minutes vs 0.77 mg/kg per minute at 210 minutes in gliclazide group (P < .05); median time, 85 vs 195 minutes, respectively (P < .05)]. The area under the curve (30-150) for EGP was significantly greater in the gliclazide group than in the nondiabetic control group (109 +/- 11 vs 198 +/- 22 mg/kg per min(2); P > .02) but not significantly different in the repaglinide group (153 +/- 25 mg/kg per min(2); P = .17). Repaglinide has minimal physiological advantage over gliclazide, but both therapies for type 2 diabetes fall far short of correcting the endocrine and metabolic abnormalities. (c) 2004 Elsevier Inc. All rights reserved.
Author(s): Singhal P, Caumo A, Cobelli C, Taylor R
Publication type: Article
Publication status: Published
ISSN (print): 0026-0495
ISSN (electronic): 1532-8600
Publisher: WB Saunders Co.
Altmetrics provided by Altmetric